MedPath

Prognosis of Guillain-Barré Syndrome in Children.

Completed
Conditions
acute inflammatory demyelinating polyneuropathy (AIDP)
no lay-term
10034606
Registration Number
NL-OMON33503
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

· Fulfilling the diagnostic criteria for GBS [Asbury 1990]
· Age of diagnosis of GBS 18 years or less
· Diagnosis of GBS was made in 1987 or thereafter
· Patients were either treated at the ward or outpatient clinic of the department of Paediatric Neurology of the Sophia Children*s Hospital, Erasmus MC, or were included in the earlier clinical trials of the GBS study group of the Erasmus MC
· Written informed consent given by the patient and/or parents/care takers

Exclusion Criteria

· Additional diseases or disorders at the time of diagnosis that may influence the endpoints
· Diagnosis of GBS less than 6 month ago

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Main study parameter/endpoint<br /><br>Residual effects on long-term outcome, with respect to nerve physiology<br /><br>dysfunction, neurological impairment, restrictions in daily activity and<br /><br>participation, and quality of life. Long-term outcome will be defined at least<br /><br>six months from diagnosis, the period in which most recovery occurs. The<br /><br>outcome levels will be determined by using various questionnaires and physical<br /><br>tests that are validated for the appropriate age categories. By using these<br /><br>tests, preferably the results obtained in patients from various ages can be<br /><br>combined. </p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath